 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- | ZP-002 / Zambon
Preclinical, Journal: Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ receptors. (Pubmed Central) - Mar 24, 2020
Moreover, chronically administered in APPswe mice during 2 months, OZP002 prevented learning deficits (in all tests plus place learning in the water-maze) and increased biochemical markers. This study shows that σ PM with high neuropotective potential can be identified, combining pharmacological efficacy, selectivity and therapeutic safety, and identifies a novel promising compound, OZP002.